Ruxolitinib in Estrogen Receptor Positive Breast Cancer

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor: Abramson Cancer Center at Penn Medicine
Study ID: NCT01594216
Phase: PHASE2
Status: Completed

Conditions

Estrogen-receptor Positive Invasive Metastatic Breast Cancer

Eligibility Criteria

Sex: FEMALE
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Ruxolitinib — DRUG
Exemestane — DRUG

Study Details

This is a Phase II investigator-Initiated trial of the Investigational Drug, Ruxolitinib, in combination with Exemestane in patients with estrogen-receptor positive advanced breast cancer. The objective of this study is to determine the preliminary safety and efficacy of the combination of exemestane and Ruxolitinib (INCB018424).

Key Dates

Start date: Apr 30, 2012
Status verified: May 2024
Primary completion: Apr 30, 2016
Completion: Apr 9, 2016

Study Design

Enrollment: 25 participants (actual)
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: First Stage
Ruxolitinib at 25 mg orally, twice daily and Exemestane, 25 mg orally once daily
Experimental: Second Stage
Ruxolitinib at 15 mg orally, twice daily and Exemestane, 25 mg orally once daily

Primary Outcome Measure

Number of Participants With Adverse Events [ Time Frame: 3 years ]

Locations (1)

Facility	City	State	ZIP	Site coordinators
Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania	10104	-

Find similar trials in Philadelphia, PA

By research site

Abramson Cancer Center of the University of Pennsylvania· Philadelphia, PA